News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Element5’s Agentic AI platform will be integrated with the HCHB EHR
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Bayer expects 2025 to be the most difficult year of its turnaround
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Subscribe To Our Newsletter & Stay Updated
